Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Glucocorticoid administration in antiemetic therapy: is it safe?

Münstedt K, Borces D, Bohlmann MK, Zygmunt M, von Georgi R.

Cancer. 2004 Oct 1;101(7):1696-702.

2.

Glucocorticoid administration in antiemetic therapy: Is it safe?

Rutz HP, Herr I.

Cancer. 2005 Jun 15;103(12):2656; author reply 2656-7. No abstract available.

3.

Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.

Estes JM, Leath CA 3rd, Straughn JM Jr, Rocconi RP, Kirby TO, Huh WK, Barnes MN 3rd.

J Am Coll Surg. 2006 Oct;203(4):527-32. Epub 2006 Aug 17.

PMID:
17000397
4.
5.

A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.

Secord AA, Havrilesky LJ, O'Malley DM, Bae-Jump V, Fleming ND, Broadwater G, Cohn DE, Gehrig PA.

Gynecol Oncol. 2009 Sep;114(3):442-7. doi: 10.1016/j.ygyno.2009.06.005. Epub 2009 Jun 26.

PMID:
19560193
6.

Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis.

Möbus V, Kieback DG, Kaubitzsch SK.

Anticancer Res. 2007 May-Jun;27(3B):1581-7.

7.

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.

Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P.

Gynecol Oncol. 2007 Jan;104(1):176-80. Epub 2006 Sep 25.

PMID:
16996584
8.

Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.

Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Frigerio L, Mereu L, Ghezzi F, Manzione L, Lauria R, Breda E, Alletti DG, Ballardini M, Vernaglia A, Sorio R, Tumolo S, Musso P, Magni G, Pisano C, Morabito A.

Crit Rev Oncol Hematol. 2009 Sep;71(3):233-41. doi: 10.1016/j.critrevonc.2008.12.010. Epub 2009 Jan 28.

PMID:
19179095
9.

Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival.

Brandwein-Gensler M, Teixeira MS, Lewis CM, Lee B, Rolnitzky L, Hille JJ, Genden E, Urken ML, Wang BY.

Am J Surg Pathol. 2005 Feb;29(2):167-78.

PMID:
15644773
10.

Indicators of survival duration in ovarian cancer and implications for aggressiveness of care.

von Gruenigen V, Daly B, Gibbons H, Hutchins J, Green A.

Cancer. 2008 May 15;112(10):2221-7. doi: 10.1002/cncr.23391.

11.

[Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].

Zou GR, Zhang YJ, Xie FY, Zheng W, Li HX, Xia YF, Lin TY, Lu TX.

Ai Zheng. 2006 Dec;25(12):1543-9. Chinese.

PMID:
17166383
13.

Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy.

Haynes DS, O'Malley M, Cohen S, Watford K, Labadie RF.

Laryngoscope. 2007 Jan;117(1):3-15. Review.

PMID:
17202923
15.

Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.

Eitan R, Kushnir M, Lithwick-Yanai G, David MB, Hoshen M, Glezerman M, Hod M, Sabah G, Rosenwald S, Levavi H.

Gynecol Oncol. 2009 Aug;114(2):253-9. doi: 10.1016/j.ygyno.2009.04.024. Epub 2009 May 14.

PMID:
19446316
16.

Glucocorticosteroid receptors in ovarian carcinomas.

Woenckhaus J, Franke FE, Hackethal A, Von Georgi R, Münstedt K.

Oncol Rep. 2006 May;15(5):1137-40.

PMID:
16596175
17.

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME.

J Clin Oncol. 2008 Dec 1;26(34):5530-6. doi: 10.1200/JCO.2008.16.1703. Epub 2008 Oct 27.

PMID:
18955455
18.

Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.

Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, Alberti P, Lusa L, Ditto A, Ferrini S, Pierotti MA, Barbareschi M, Pilotti S, Canevari S.

Clin Cancer Res. 2008 Mar 15;14(6):1726-33. doi: 10.1158/1078-0432.CCR-07-0428.

19.

Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.

Jones E, Koyama T, Ho RH, Kuttesch J, Shankar S, Whitlock JA, Cartwright J, Frangoul H.

Pediatr Blood Cancer. 2007 Mar;48(3):330-2.

PMID:
16304666
20.

Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.

Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, Aydin Y, Topuz E.

Gynecol Oncol. 2008 Jan;108(1):136-40. Epub 2007 Oct 23.

PMID:
17936342

Supplemental Content

Support Center